• Policy
• Losartan, which has a high proportion of consignment
• by Lee, Tak-Sun Nov 25, 2021 05:55am

• Policy
• Discussions began on the scope of Mifegymiso license
• by Lee, Tak-Sun Nov 24, 2021 05:53am

• Policy
• Betmiga PR prices fluctuated 3 times Between 15 days
• by Kim, Jung-Ju Nov 24, 2021 05:53am

• Policy
• MFDS cautious on waiving bridging trial for abortion pill
• by Choi-sun Nov 24, 2021 05:53am

• Policy
• Nam In-soon's drug price recovery bill excludes rebates
• by Lee, Jeong-Hwan Nov 23, 2021 05:55am

• Policy
• Brilinta’s price cut 30%, Nexavar’s premium stays 1 year
• by Kim, Jung-Ju Nov 23, 2021 05:54am

• Policy
• Benefit for 46 generics for Eliquis will be kicked out
• by Kim, Jung-Ju Nov 22, 2021 05:52am

• Policy
• Lixiana latecomers apply for approval as an ODT
• by Lee, Tak-Sun Nov 22, 2021 05:52am

• Policy
• AML drug that returned after 7 years is approved in Korea
• by Lee, Tak-Sun Nov 19, 2021 05:52am

• Policy
• The CSO reporting system will be reviewed
• by Lee, Jeong-Hwan Nov 19, 2021 05:52am